Egetis Therapeutics AB (publ) (EGTX.ST)
- Previous Close
3.2550 - Open
3.3050 - Bid 3.3600 x --
- Ask 3.3650 x --
- Day's Range
3.3000 - 3.3800 - 52 Week Range
3.2550 - 9.3000 - Volume
173,336 - Avg. Volume
527,512 - Market Cap (intraday)
1.207B - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0000 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
www.egetis.comRecent News: EGTX.ST
View MorePerformance Overview: EGTX.ST
Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EGTX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EGTX.ST
View MoreValuation Measures
Market Cap
1.17B
Enterprise Value
995.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.80
Price/Book (mrq)
2.70
Enterprise Value/Revenue
21.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.92%
Return on Equity (ttm)
-73.19%
Revenue (ttm)
46.7M
Net Income Avi to Common (ttm)
-331.5M
Diluted EPS (ttm)
-1.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
272.8M
Total Debt/Equity (mrq)
24.58%
Levered Free Cash Flow (ttm)
-124.72M